» Articles » PMID: 36144670

Low Temperature Plasma Suppresses Lung Cancer Cells Growth Via VEGF/VEGFR2/RAS/ERK Axis

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 Sep 23
PMID 36144670
Authors
Affiliations
Soon will be listed here.
Abstract

Low temperature plasma (LTP) is a promising cancer therapy in clinical practice. In this study, dielectric barrier discharge plasma with helium gas was used to generate LTP. Significant increases in extracellular and intracellular reactive species were found in lung cancer cells (CALU-1 and SPC-A1) after LTP treatments. Cells viability and apoptosis assays demonstrated that LTP inhibited cells viability and induced cells death, respectively. Moreover, Western blotting revealed that the growth of CALU-1 cells was suppressed by LTP via the VEGF/VEGFR2/RAS/ERK axis for the first time. The results showed that LTP-induced ROS and RNS could inhibit the growth of lung cancer cells via VEGF/VEGFR2/RAS/ERK axis. These findings advance our understanding of the inhibitory mechanism of LTP on lung cancer and will facilitate its clinical application.

Citing Articles

Plasma-Activated Medium Inhibited the Proliferation and Migration of Non-Small Cell Lung Cancer A549 Cells in 3D Culture.

Sun Z, Ding C, Wang Y, Lu T, Song W Int J Mol Sci. 2025; 25(24.

PMID: 39769029 PMC: 11676436. DOI: 10.3390/ijms252413262.


Effects and Mechanisms of Non-Thermal Plasma-Mediated ROS and Its Applications in Animal Husbandry and Biomedicine.

Yang Y, Wang Y, Wei S, Wang X, Zhang J Int J Mol Sci. 2023; 24(21).

PMID: 37958872 PMC: 10648079. DOI: 10.3390/ijms242115889.


Current Status and Future Trends of Cold Atmospheric Plasma as an Oncotherapy.

Dai X, Wu J, Lu L, Chen Y Biomol Ther (Seoul). 2023; 31(5):496-514.

PMID: 37641880 PMC: 10468422. DOI: 10.4062/biomolther.2023.027.


Low-Temperature Plasma-Activated Medium Inhibits the Migration of Non-Small Cell Lung Cancer Cells via the Wnt/-Catenin Pathway.

Zhang Y, Yan Z, Wu H, Yang X, Yang K, Song W Biomolecules. 2023; 13(7).

PMID: 37509109 PMC: 10377075. DOI: 10.3390/biom13071073.

References
1.
Ramakrishnan V, Timm M, Haug J, Kimlinger T, Halling T, Wellik L . Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol. 2011; 87(3):277-83. PMC: 3465673. DOI: 10.1002/ajh.22263. View

2.
Chen G, Chen Z, Wen D, Wang Z, Li H, Zeng Y . Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy. Proc Natl Acad Sci U S A. 2020; 117(7):3687-3692. PMC: 7035610. DOI: 10.1073/pnas.1917891117. View

3.
von Woedtke T, Schmidt A, Bekeschus S, Wende K, Weltmann K . Plasma Medicine: A Field of Applied Redox Biology. In Vivo. 2019; 33(4):1011-1026. PMC: 6689367. DOI: 10.21873/invivo.11570. View

4.
Hilger R, Scheulen M, Strumberg D . The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2003; 25(6):511-8. DOI: 10.1159/000068621. View

5.
Song Y, Dai F, Zhai D, Dong Y, Zhang J, Lu B . Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis. 2012; 15(3):421-32. DOI: 10.1007/s10456-012-9270-4. View